Amer Zeidan: Two additional studies from EHA2024 confirm validity of IWG2023

Amer Zeidan shared on X:               .

“Two additional studies from EHA2024 (one from a large Austrian registry and another from ASCERTAIN trial) confirm validity of IWG2023 higher risk MDS (Myelodysplastic Syndrome) response criteria and support using them to assess clinical benefits in trials of novel agents instead of the old 2006 criteria.”

Source: Amer Zeidan/X

Amer Zeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid Malignancies DART (Disease Aligned Research Team), and the director of Continuing Medical Education (CME) at the Hematology division and chairs the Protocol Review Committee (PRC) at Yale Cancer Center.

Dr. Zeidan is a well-known leukemia researcher with a special focus on targeted therapies and immunotherapy for myeloid malignancies, and a social media influencer in the field of blood cancer.